Through its clinical trials, Capricor Therapeutics is actively engaged in the development of novel therapeutics to prevent and treat serious diseases.
Capricor’s Phase 2 INSPIRE study enrolled patients who have a confirmed diagnosis of SARS-CoV-2.
Capricor completed the HOPE-2 clinical trial for Capricor’s lead investigational therapy, CAP-1002.
HOPEPHASE I/II enrollment complete
The Halt cardiomyOPathy progrEssion in Duchenne (HOPE) Phase I/II trial will evaluate CAP-1002 in patients with Duchenne muscular dystrophy associated cardiomyopathy.